|
1
|
Moran AE, Forouzanfar MH, Roth GA, Mensah
GA, Ezzati M, Murray CJ and Naghavi M: Temporal trends in ischemic
heart disease mortality in 21 world regions, 1980 to 2010: The
Global Burden of Disease 2010 study. Circulation. 129:1483–1492.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Piper HM, Meuter K and Schäfer C: Cellular
mechanisms of ischemia-reperfusion injury. Ann Thorac Surg.
75:(Suppl). S644–S648. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Penna C, Mancardi D, Raimonodo S, Geuna S
and Pagliaro P: The paradigm of postconditioning to protect the
heart. J Cell Mol Med. 12:435–458. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Sharma V, Bell RM and Yellon DM: Targeting
reperfusion injury in acute myocardial infarction: A review of
reperfusion injury pharmacotherapy. Expert Opin Pharmacother.
13:1153–1175. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Nogueira-Machado JA and de Oliveira Volpe
CM: HMGB-1 as a target for inflammation controlling. Recent Pat
Endocr Metab Immune Drug Discov. 6:201–209. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Funayama A, Shishido T, Netsu S, et al:
Cardiac nuclear high mobility group box 1 prevents the development
of cardiac hypertrophy and heart failure. Cardiovasc Res.
99:657–664. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Jia Z, Xue R, Liu G, et al: HMGB1 is
involved in the protective effect of the PPAR a agonist fenofibrate
against cardiac hypertrophy. PPAR Res. 2014:5413942014. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Andrassy M, Volz HC, Igwe JC, et al:
High-mobility group box-1 in ischemia-reperfusion injury of the
heart. Circulation. 117:3216–3226. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Zhu H, Li J, Wang S, Liu K, Wang L and
Huang L: Hmgb1-TLR4-IL-23-IL-17A axis promote ischemia-reperfusion
injury in a cardiac transplantation model. Transplantation.
95:1448–1454. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Wang GL, Jiang BH, Rue EA and Semenza GL:
Hypoxia-inducible factor 1 is a basic-helix-loop-helix-PAS
heterodimer regulated by cellular O2 tension. Proc Natl
Acad Sci USA. 92:5510–5514. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Semenza GL: Hypoxia-inducible factor 1 and
cardiovascular disease. Annu Rev Physiol. 76:39–56. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Chu W, Wan L, Zhao D, et al: Mild
hypoxia-induced cardiomyocyte hypertrophy via up-regulation of
HIF-1α-mediated TRPC signaling. J Cell Mol Med. 16:2022–2034. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Scaffidi P, Misteli T and Bianchi ME:
Release of chromatin protein HMGB1 by necrotic cells triggers
inflammation. Nature. 418:191–195. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Mozaffari MS, Liu JY, Abebe W and Baban B:
Mechanisms of load dependency of myocardial ischemia reperfusion
injury. Am J Cardiovasc Dis. 3:180–196. 2013.PubMed/NCBI
|
|
15
|
Smith RD, Yokoyama H, Averill DB, Cooke L,
Brosnihan KB, Schiffrin EL and Ferrario CM: The protective effects
of angiotensin II blockade with olmesartan medoxomil on resistance
vessel remodeling (The VIOS study): Rationale and baseline
characteristics. Am J Cardiovasc Drugs. 6:335–342. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Lorenzen JM, Neunhöffer H, David S,
Kielstein JT, Haller H and Fliser D: Angiotensin II receptor
blocker and statins lower elevated levels of osteopontin in
essential hypertension - results from the EUTOPIA trial.
Atherosclerosis. 209:184–188. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Hirohata A, Yamamoto K, Miyoshi T, et al:
Four-year clinical outcomes of the OLIVUS-Ex (impact of Olmesartan
on progression of coronary atherosclerosis: Evaluation by
intravascular ultrasound) extension trial. Atherosclerosis.
220:134–138. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Swindle JP, Buzinec P, Iorga SR, Ramaswamy
K and Panjabi S: Long-term clinical and economic outcomes
associated with angiotensin II receptor blocker use in hypertensive
patients. Curr Med Res Opin. 27:1719–1731. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Hamamoto Y and Koshiyama H: ROADMAP and
ORIENTAL Trails: The Re-emergence of J-Curve Ghost? Jpn Clin Med.
2:25–28. 2011.PubMed/NCBI
|
|
20
|
Zhou EH, Gelperin K, Levenson MS, Rose M,
Hsueh YH and Graham DJ: Risk of acute myocardial infarction,
stroke, or death in patients initiating olmesartan or other
angiotensin receptor blockers - a cohort study using the Clinical
Practice Research Datalink. Pharmacoepidemiol Drug Saf. 23:340–347.
2014. View
Article : Google Scholar : PubMed/NCBI
|
|
21
|
Lim SY, Davidson SM, Hausenloy DJ and
Yellon DM: Preconditioning and postconditioning: The essential role
of the mitochondrial permeability transition pore. Cardiovasc Res.
75:530–535. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Pourkhalili K, Hajizadeh S, Tiraihi T,
Akbari Z, Esmailidehaj M, Bigdeli MR and Khoshbaten A: Ischemia and
reperfusion-induced arrhythmias: Role of hyperoxic preconditioning.
J Cardiovasc Med (Hagerstown). 10:635–642. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Zhao H, Wang Y, Wu Y, et al:
Hyperlipidemia does not prevent the cardioprotection by
postconditioning against myocardial ischemia/reperfusion injury and
the involvement of hypoxia inducible factor-1alpha upregulation.
Acta Biochim Biophys Sin (Shanghai). 41:745–753. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Yoshida A, Suzuki N, Nakano Y, Oho T,
Kawada M and Koga T: Development of a 5′fluorogenic nuclease-based
real-time PCR assay for quantitative detection of Actinobacillus
actinomycetemcomitans and Porphyromonas gingivalis. J Clin
Microbiol. 41:863–866. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Paulis L and Unger T: Novel therapeutic
targets for hypertension. Nat Rev Cardiol. 7:431–441. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Dai W and Kloner RA: Potential role of
renin-angiotensin system blockade for preventing myocardial
ischemia/reperfusion injury and remodeling after myocardial
infarction. Postgrad Med. 123:49–55. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Wassmann S and Nickenig G:
Pathophysiological regulation of the AT1-receptor and implications
for vascular disease. J Hypertens Suppl. 24:S15–S21. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Chilman-Blair K and Rabasseda X:
Olmesartan, an AT1-selective antihypertensive agent. Drugs Today
(Barc). 39:745–761. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Montecucco F, Pende A, Quercioli A and
Mach F: Inflammation in the pathophysiology of essential
hypertension. J Nephrol. 24:23–34. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Rodríguez-Iturbe B, Ferrebuz A, Vanegas V,
Quiroz Y, Mezzano S and Vaziri ND: Early and sustained inhibition
of nuclear factor-kappaB prevents hypertension in spontaneously
hypertensive rats. J Pharmacol Exp Ther. 315:51–57. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Portaluppi F, Boari B and Manfredini R:
Oxidative stress in essential hypertension. Curr Pharm Des.
10:1695–1698. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Tang D, Kang R, Xiao W, et al: Nuclear
heat shock protein 72 as a negative regulator of oxidative stress
(hydrogen peroxide)-induced HMGB1 cytoplasmic translocation and
release. J Immunol. 178:7376–7384. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Su FF, Shi MQ, Guo WG, Liu XT, Wang HT, Lu
ZF and Zheng QS: High-mobility group box 1 induces
calcineurin-mediated cell hypertrophy in neonatal rat ventricular
myocytes. Mediators Inflamm. 2012:8051492012. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Krishnan J, Suter M, Windak R, et al:
Activation of a HIF1 alpha-PPARgamma axis underlies the integration
of glycolytic and lipid anabolic pathways in pathologic cardiac
hypertrophy. Cell Metab. 9:512–524. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Shyu KG, Liou JY, Wang BW, Fang WJ and
Chang H: Carvedilol prevents cardiac hypertrophy and overexpression
of hypoxia-inducible facor-1alpha and vascular endothelial growth
factor in pressure-overloaded rat heart. J Biomed Sci. 12:409–420.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Kikuchi K, Tancharoen S, Ito T, et al:
Potential of the angiotensin receptor blockers (ARBs) telmisartan,
irbesartan and candesartan for inhibiting the HMGB1/RAGE axis in
prevention and acute treatment of stroke. Int J Mol Sci.
14:18899–18924. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Fu M, Zhou J, Xu J, et al: Olmesartan
attenuates cardiac hypertrophy and improves cardiac diastolic
function in spontaneously hypertensive rats through inhibition of
calcineurin pathway. J Cardiovasc Pharmacol. 63:218–226. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Opie LH: Reperfusion injury and its
pharmacologic modification. Circulation. 80:1049–1062. 1989.
View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Zhang X, Wheeler D, Tang Y, et al:
Calcium/calmodulin-dependent protein kinase (CaMK) IV mediates
nucleocytoplasmic shuttling and release of HMGB1 during
lipopolysaccharide stimulation of macrophages. J Immunol.
181:5015–5023. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Tang D, Kang R, Zeh HJ III and Lotze MT:
High-mobility group box 1, oxidative stress and disease. Antioxid
Redox Signal. 14:1315–1335. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Dai W, Hale SL, Kay GL, Jyrala AJ and
Kloner RA: Cardioprotective effects of angiotensin II type 1
receptor blockade with olmesartan on reperfusion injury in a rat
myocardial ischemia-reperfusion injury model. Cardiovasc Ther.
28:30–37. 2010. View Article : Google Scholar : PubMed/NCBI
|
